Serinus Biosciences Funding & Investors

Serinus Biosciences develops technologies to understand how chemicals work inside malignant tumor cells. They are developing a new generation of AI for drug development by leveraging knowledge-primed models and cancer biology. Their technique makes it possible to create medicines that are effective for a variety of patient groups, bypass resistance mechanisms, and support combinations by design. Serinus Biosciences is headquartered in New York City, New York and was founded in 2022.